MAGEA2 (Melanoma-Associated Antigen A2) is a cancer-testis antigen aberrantly expressed in multiple malignancies but absent in normal somatic cells 1. In embryonic stem cells, MAGEA2 promotes pluripotency and proliferation; its knockdown increases Erk1/2 phosphorylation, induces S-phase cell cycle arrest, and triggers caspase-dependent apoptosis 1. Mechanistically, MAGEA2 functions through the p53 pathway by binding histone deacetylase 3 (HDAC3) and interfering with p53 acetylation at PML-nuclear bodies, thereby suppressing p53-dependent senescence and apoptosis 2. In cancer contexts, MAGEA2 overexpression correlates with poor prognosis across lung adenocarcinoma, head and neck squamous cell carcinoma, and glioma 345. MAGEA2 inhibition effectively suppresses cancer cell growth and restores chemotherapeutic sensitivity 367. In pancreatic cancer, MAGEA2 specifically blocks gemcitabine-induced JNK-c-Jun-p53 apoptosis while promoting tumor-stromal crosstalk-mediated chemoresistance 7. These findings establish MAGEA2 as an independent prognostic biomarker and promising therapeutic target across multiple cancer types.